AI
FOLD

Atom Investors’s Amicus Therapeutics FOLD Stock Holding History

Atom Investors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-16,362
Closed -$159K – 343
2019
Q4 		$159K Buy
+16,362
New +$150K 0.01% 228
2019
Q1 		– Sell
-184,862
Closed -$1.77M – 580
2018
Q4 		$1.77M Buy
+184,862
New +$2.03M 0.17% 118

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Atom Investors's FOLD Position: Q1 2020 in Review

Atom Investors sold out of Amicus Therapeutics (FOLD) in Q1 2020, closing a stake of 16,362 shares — an estimated $159K sold.

Atom Investors first reported a position in FOLD in Q4 2018 and held it in 2 quarters. The position peaked at $1.77M in Q4 2018. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2020.

  • Atom Investors reported no remaining Amicus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Atom Investors sold 16,362 Amicus Therapeutics shares in Q1 2020, an estimated $159K.
  • Atom Investors first reported a position in Amicus Therapeutics in Q4 2018 and held it in 2 quarters.
  • Atom Investors's Amicus Therapeutics position peaked at $1.77M in Q4 2018.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2020.

Based on Atom Investors's 13F filing for Q1 2020, filed 15 May 2020.